title: Anti-tuberculosis drug inducd hepatitis - a Sri Lankan experience.
abstract: OBJECTIVE
  To assess the incidence of anti-tuberculosis (TB) drug induced hepatitis (AIH) in Sri Lankan patients, determine risk factors of AIH, and to address management options in AIH.
  
  
  METHODS
  A prospective study.
  
  
  METHODS
  Chest Hospital, Welisara, Sri Lanka, from April 2001 to April 2002.
  
  
  METHODS
  Seven hundred and eighty three patients with a confirmed diagnosis of TB and resident in the Colombo and Gampaha districts who presented to Chest Hospital, Welisara, Sri Lanka.
  
  
  METHODS
  WHO recommended treatment was commenced in all cases. AIH was diagnosed when patients complained of decreased appetite with nausea or vomiting and elevated serum bilirubin (SB; >1.1 mg/dL) or elevated serum alanine transferase (ALT; > 3 times upper limit of normal).
  
  
  RESULTS
  Of 783 enrolled patients, 74 (9.5%) developed AIH, the majority (58%) developing AIH within the first 2 weeks of the intensive phase of treatment. AIH was more common among patients over 60 years (p = 0.018), who developed pulmonary TB (p = 0.028), and in patients weighing 33-55 kg (p = 0.004). Age, weight and rifampicin overdosage were significant predictors of AIH. Of the 74 AIH patients, standard treatment was restarted in 60, treatment modified in six, two defaulted and six died.
  
  
  CONCLUSIONS
  The incidence of AIH in Sri Lanka is 9.5% in treated patients. AIH was associated with age, low body weight and rifampicin overdosage.
authors.affiliation: Chest Hospital, Welisara, Sri Lanka.
authors.forename: W V
authors.initials: WV
authors.lastname: Senaratne
authors.forename: M J
authors.initials: MJ
authors.lastname: Pinidiyapathirage
authors.forename: G A M H E
authors.initials: GA
authors.lastname: Perera
authors.forename: A R
authors.initials: AR
authors.lastname: Wickremasinghe
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology* / Q000209:etiology; D002648:Child; D005260:Female; D006801:Humans; D015994:Incidence; D007538:Isoniazid / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012293:Rifampin / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D013188:Sri Lanka / Q000453:epidemiology; D013307:Streptomycin / Q000009:adverse effects*; D014376:Tuberculosis / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin